Table 4.
Comparison of MCI male participants in the DOD and NIH funded studies.
| Variable | NIH Male MCI | DOD Male MCI | p-valuea |
|---|---|---|---|
| Age, mean (SD), y | 72.5 (7.1) (n=315) |
69.8 (3.7) (n=49) |
<.001 |
| APOE ε4+, % | 47.5 (n=301) |
20.4 (n=44) |
<.001 |
| ADAS-Cog Total 13, mean (SD) | 16.1 (6.5) (n=316) |
15.1 (5.4) (n=49) |
.75 |
| MMSE, mean (SD) | 28.0 (1.7) (n=317) |
27.4 (2.1) (n=49) |
<.001 |
| Florbetapir cortical SUVR, mean (SD) |
1.22 (0.23) (n=286) |
1.19 (0.17) (n=42) |
.23 |
| Florbetapir positive, % | 55.2 (n=286) |
38.1 (n=42) |
.98 |
| Hippocampus, mean (SD), % of intracranial volume | 0.46 (0.08) (n=248) |
0.50 (0.07) (n=33) |
.03 |
| White matter Hyperintensities volume, mean (SD) |
6.8 (9.1) (n=316) |
4.9 (5.2) (n=38) |
.85 |
| CSF Aβ42, mean (SD), pg/ml | 1034.0 (554.9) (n=291) |
1196.5 (550.5) (n=25) |
.67 |
| CSF t-tau, mean (SD), pg/ml | 260.3 (111.2) (n=291) |
263.0 (151.2) (n=25) |
.10 |
| CSF p-tau181, mean (SD), pg/ml | 25.1 (12.5) (n=291) |
25.2 (17.1) (n=24) |
.10 |
a
Age and APOE ε4+ prevalence was compared between groups using the two-sample t-test and chi-square test, respectively. All other variables were tested using a linear or generalized linear regression model adjusted for age and APOE ε4 status.
Abbreviations: ADAS-cog, Alzheimer’s disease assessment scale-cognitive subscale; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; MMSE, mini-mental state examination; PTSD, post-traumatic stress disorder; SUVR, standardized uptake volume ratio; TBI, traumatic brain injury.